Who's got some Investment Ideas?

Anything off-topic

Moderators: Eric@PPE, James B., flyingpolarbear, VicC

CrazyHoe
Posts: 6228
Joined: Tue Feb 19, 2008 8:30 am
Location: Mtl; '98 2dr4x4 Tahoe, L31,Hookers Long T, 0411,EFIlive, 4L80-E,dual 3",marine int+inj

Post by CrazyHoe »

Bought AAL too :wink:

Speeder
Posts: 10772
Joined: Fri Apr 30, 1999 9:12 pm
Location: 2015 Tahoe 2WD 5.3L 6L80E, 2008 Colorado work beater, 2003 Dodge Dakota pro-touring project

Re: Who's got some Investment Ideas?

Post by Speeder »

Bailed out of AAL at 20 and a bit. Was making me nervous, especially after the drop from the 15 I bought at to 9 after Buffet sold out.

flyingpolarbear
Posts: 23
Joined: Thu Feb 29, 1996 2:26 am
Location: Fullerton, California

Re: Who's got some Investment Ideas?

Post by flyingpolarbear »

I'm buying a lot of Galectin Therapeutics (GALT) right now.

GALT is developing a Galectin-3 inhibitor drug GR-MD-02 (belapectin) which looks very promising for many inflammatory and fibrotic diseases. The Chairman of the Board, and largest investor, is billionaire Richard Uihlein (founder and CEO of ULINE). The stock is trading at a discount because it just went through a lengthy clinical trial planning period, and now has momentum heading higher because they just launched the Phase 2b/3 adaptive clinical trial for NASH cirrhosis (pharma industry's #1 untapped indication).

Several big pharma companies have expressed interested in "acquiring NASH assets" (buyout or licensing partnership) including BMY, MRK, PFE, SNY, GILD so the chances are decent for M&A activity. GALT converted all of its preferred stock to common stock last year, which is a clue that they might be cleaning up the capital structure possibly in the midst of deal talks.

To get some idea of the potential of GR-MD-02, here are research papers (several in world's top journals including Nature and JACC) published just in the past couple years, which specifically mention the company's drug under development:

---

Jun 2020 – Galectin-3 Released by Pancreatic Ductal Adenocarcinoma
https://www.frontiersin.org/articles/10 ... 01328/full

---

Jun 2020 – A potential role for Galectin-3 inhibitors in the treatment of COVID-19
https://peerj.com/articles/9392/

---

Jun 2020 – Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease
JACC State-of-the-Art Review

https://www.onlinejacc.org/content/75/21/2726

---

Antiarrhythmic Drugs (Current Cardiovascular Therapy) 1st ed. 2020 Edition

https://www.amazon.com/Antiarrhythmic-D ... 3030348911

---

May 2020 – Therapeutic Landscape for NAFLD in 2020

"Directly antifibrotic drugs include molecules that block the galectin-3 receptor on stellate cells. A study of one such drug, belapectin (GR-MD-02), was shown to reduce the hepatic-portal vein pressure gradient in patients with cirrhosis but without varices (NASH-CX, NCT02462967), and a further trial of belapectin is in development."

https://www.gastrojournal.org/article/S ... 5/abstract

---

Apr 2020 – Amino Acid Deletions in HIV-1 Ameliorate Galectin-3 Mediated Enhancement in Viral Budding

“There are some recognized galectin-3 inhibitors, such as TD139 and GR-MD-02, which are proven to have the potential to treat fibrosis and may be considered for the usage of HIV-1 treatment [48]."

https://www.mdpi.com/1422-0067/21/8/2910/htm

---

Apr 2020 – An In Situ Hyaluronic Acid-Fibrin Hydrogel Containing Drug-Loaded Nanocapsules for Intra-Articular Treatment of Inflammatory Joint Diseases


https://link.springer.com/article/10.10 ... 20-00154-2

---

Mar 2020 – The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer

https://www.mdpi.com/2073-4409/9/3/689

---

Feb 2020 – Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy

https://www.sciencedirect.com/science/a ... 1819324193

---

Jan 2020 – Tumor Microenvironment-Associated Extracellular Matrix Components Regulate NK Cell Function

https://www.frontiersin.org/articles/10 ... 00073/full

---

Jan 2020 – Galectin-3 as a modifier of anti-microbial immunity: Unravelling the unknowns

"Therefore, modifying galectin-3 function in CD8+ T cells could help achieve better protection during viral infection."

https://academic.oup.com/glycob/advance ... 05/5716259

---

Dec 2019 – Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension.

Results
“2 mg/kg belapectin was associated with a reduction in HVPG at 52 weeks compared with baseline (P=.02) and reduced development of new varices (P=.03). Belapectin (2 mg/kg) was well tolerated and produced no safety signals.”

https://www.gastrojournal.org/article/S ... 7/fulltext

---

Apr 2019 – Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis.

"The functional significance of Gal-3 in PH was assessed using two structurally distinct Gal-3 inhibitors, GM-CT-01 and GR-MD-02 in the MCT model. The rationale for using two compounds was to improve pharmacological rigor in that inhibitors with similar targets but distinct structures are unlikely to share the same non-specific actions. We found that both inhibitors had similar efficacy, and did not observe any toxicity/adverse effects at the doses employed. We found that both Gal-3 inhibitors (GM and GR) significantly decreased RV hypertrophy as compared to MCT alone."

https://www.physiology.org/doi/abs/10.1 ... 00186.2018

---

Apr 2019 – Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities

“Inhibition of Gal3 with GR- MD-02, a polysaccharide polymer with high affinity for Gal3, increased survival in the TRAMP-C1 prostate cancer cell line model, and this agent has also been tested in combination with immunotherapy in ongoing clinical trials designed for melanoma, non- small cell lung cancer and head and neck squamous cell carcinoma.”

https://www.nature.com/articles/s41585-019-0183-5

---

Mar 2019 – Galectin-3 Inhibition with GR-MD-02 Synergizes with T Cell-Targeting Immunotherapy, Leading to Reduced Immune Suppression and Improved Overall Survival.

“Combination therapy of GR-MD-02/aOX40
– Increases survival & decreases lung metastases
– Clinical responders to GR-MD-02/pembro therapy have reduced Mo-MDSC post-treatment”

https://tks.keystonesymposia.org/index. ... ingID=1626

Bushwacker
Posts: 110
Joined: Wed Jul 04, 2012 4:05 pm

Re: Who's got some Investment Ideas?

Post by Bushwacker »

flyingpolarbear wrote:
Wed Jul 15, 2020 6:19 pm
I'm buying a lot of Galectin Therapeutics (GALT) right now.

GALT is developing a Galectin-3 inhibitor drug GR-MD-02 (belapectin) which looks very promising for many inflammatory and fibrotic diseases. The Chairman of the Board, and largest investor, is billionaire Richard Uihlein (founder and CEO of ULINE). The stock is trading at a discount because it just went through a lengthy clinical trial planning period, and now has momentum heading higher because they just launched the Phase 2b/3 adaptive clinical trial for NASH cirrhosis (pharma industry's #1 untapped indication).

Several big pharma companies have expressed interested in "acquiring NASH assets" (buyout or licensing partnership) including BMY, MRK, PFE, SNY, GILD so the chances are decent for M&A activity. GALT converted all of its preferred stock to common stock last year, which is a clue that they might be cleaning up the capital structure possibly in the midst of deal talks.

To get some idea of the potential of GR-MD-02, here are research papers (several in world's top journals including Nature and JACC) published just in the past couple years, which specifically mention the company's drug under development:

---

Jun 2020 – Galectin-3 Released by Pancreatic Ductal Adenocarcinoma
https://www.frontiersin.org/articles/10 ... 01328/full

---

Jun 2020 – A potential role for Galectin-3 inhibitors in the treatment of COVID-19
https://peerj.com/articles/9392/

---

Jun 2020 – Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease
JACC State-of-the-Art Review

https://www.onlinejacc.org/content/75/21/2726

---

Antiarrhythmic Drugs (Current Cardiovascular Therapy) 1st ed. 2020 Edition

https://www.amazon.com/Antiarrhythmic-D ... 3030348911

---

May 2020 – Therapeutic Landscape for NAFLD in 2020

"Directly antifibrotic drugs include molecules that block the galectin-3 receptor on stellate cells. A study of one such drug, belapectin (GR-MD-02), was shown to reduce the hepatic-portal vein pressure gradient in patients with cirrhosis but without varices (NASH-CX, NCT02462967), and a further trial of belapectin is in development."

https://www.gastrojournal.org/article/S ... 5/abstract

---

Apr 2020 – Amino Acid Deletions in HIV-1 Ameliorate Galectin-3 Mediated Enhancement in Viral Budding

“There are some recognized galectin-3 inhibitors, such as TD139 and GR-MD-02, which are proven to have the potential to treat fibrosis and may be considered for the usage of HIV-1 treatment [48]."

https://www.mdpi.com/1422-0067/21/8/2910/htm

---

Apr 2020 – An In Situ Hyaluronic Acid-Fibrin Hydrogel Containing Drug-Loaded Nanocapsules for Intra-Articular Treatment of Inflammatory Joint Diseases


https://link.springer.com/article/10.10 ... 20-00154-2

---

Mar 2020 – The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer

https://www.mdpi.com/2073-4409/9/3/689

---

Feb 2020 – Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy

https://www.sciencedirect.com/science/a ... 1819324193

---

Jan 2020 – Tumor Microenvironment-Associated Extracellular Matrix Components Regulate NK Cell Function

https://www.frontiersin.org/articles/10 ... 00073/full

---

Jan 2020 – Galectin-3 as a modifier of anti-microbial immunity: Unravelling the unknowns

"Therefore, modifying galectin-3 function in CD8+ T cells could help achieve better protection during viral infection."

https://academic.oup.com/glycob/advance ... 05/5716259

---

Dec 2019 – Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension.

Results
“2 mg/kg belapectin was associated with a reduction in HVPG at 52 weeks compared with baseline (P=.02) and reduced development of new varices (P=.03). Belapectin (2 mg/kg) was well tolerated and produced no safety signals.”

https://www.gastrojournal.org/article/S ... 7/fulltext

---

Apr 2019 – Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis.

"The functional significance of Gal-3 in PH was assessed using two structurally distinct Gal-3 inhibitors, GM-CT-01 and GR-MD-02 in the MCT model. The rationale for using two compounds was to improve pharmacological rigor in that inhibitors with similar targets but distinct structures are unlikely to share the same non-specific actions. We found that both inhibitors had similar efficacy, and did not observe any toxicity/adverse effects at the doses employed. We found that both Gal-3 inhibitors (GM and GR) significantly decreased RV hypertrophy as compared to MCT alone."

https://www.physiology.org/doi/abs/10.1 ... 00186.2018

---

Apr 2019 – Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities

“Inhibition of Gal3 with GR- MD-02, a polysaccharide polymer with high affinity for Gal3, increased survival in the TRAMP-C1 prostate cancer cell line model, and this agent has also been tested in combination with immunotherapy in ongoing clinical trials designed for melanoma, non- small cell lung cancer and head and neck squamous cell carcinoma.”

https://www.nature.com/articles/s41585-019-0183-5

---

Mar 2019 – Galectin-3 Inhibition with GR-MD-02 Synergizes with T Cell-Targeting Immunotherapy, Leading to Reduced Immune Suppression and Improved Overall Survival.

“Combination therapy of GR-MD-02/aOX40
– Increases survival & decreases lung metastases
– Clinical responders to GR-MD-02/pembro therapy have reduced Mo-MDSC post-treatment”
Is this going to be the next money maker? About how long will it take to pay off?I have a couple thousand I could afford to invest that I would love to make big money. Lol don't we all.
https://tks.keystonesymposia.org/index. ... ingID=1626

Ural_4320
Posts: 3
Joined: Thu Jul 30, 2020 11:09 am

Re: Who's got some Investment Ideas?

Post by Ural_4320 »

Well, I've got a pretty accurate idea, as I've spent the last couple days writing an investment strategy in this property in Greece https://residence-greece.com/! Of course, I'm not going to publish it, but I doubt anyone on this forum has a couple dozen million euros to spend on such a plan. I don't, at least. :lol2:

bembviis
Posts: 4
Joined: Sat Oct 17, 2020 9:58 am

Re: Who's got some Investment Ideas?

Post by bembviis »

Bitcoin is less interesting now than when 1 electronic money could be converted into 1000 dollars. Besides, the status of this currency is still dubious. They also talk about illegal operations, and the absence of permits for circulation within the country, etc. But investing in it still makes sense, while it is not necessary to buy the underlying asset, you can invest in various investment instruments, change btc to eth, one way or another tied to bitcoin.

Post Reply